5Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Immuneering (NASDAQ:IMRX) and maintains a $15 price target.
August 07, 2024 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Immuneering and maintains a $15 price target.
The reiteration of a Buy rating and the maintenance of a $15 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100